CD123 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THE SAME
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Feb 13, 2025
app pub date -
Jul 26, 2024
filing date -
Jul 26, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure generally relates to antibodies, antigen binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the α chain of the interleukin-3 receptor) and deliver a payload to CD123 expressing cells. The payload is a topoisomerase inhibitor that efficiently kills CD123 expressing tumor cells while sparing hematopoietic stem cells and mature hematopoietic cells.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully